Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
IMP321 NEW DATA ACCEPTED
FOR PRESENTATION AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING
SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that new data investigating the use of eftilagimod alpha
(IMP321), the Company s lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either no response or a suboptimal response to pembrolizumab, will be presented in a poster
presentation for the first time at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting.
Pushing the accelerator and releasing the
break: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma. Poster Number P259
Authors: Victoria Atkinson, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Adnan Khattak, Christian Mueller, Tina Dunkelmann, Chrystelle Brignone,
The SITC 2017 Annual Meeting is being held on November 10-12, 2017 at the Gaylord National
Hotel & Convention Center in National Harbor, Maryland.
Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble
LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products
including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima s pharmaceutical partners. Prima is also developing an agonist of LAG-3 (IMP761) for autoimmune
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information
please visit www.primabiomed.com.au.
For further information please contact:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Matthew Gregorowski,
+61 2 8234 0105; mgregorowski@citadelmagnus.com